Study of treatment starategy for patients with castration resistsnt prostate cancer using new hormonal agents before chemotherapy

Study of treatment starategy for patients with castration resistsnt prostate cancer using new hormonal agents before chemotherapy - Starategy for pre-chemo CRPC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016783

Enrollment

200

Registered

2015-04-01

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Pathologicalyconfirmation of prostate cancer 2. Castration resistant prostate cancer 3. Next treatment: Enzalutamide or abiraterone 4. No chemotherapy 5. No steroids 6. Performance status 0-1

Exclusion criteria

Exclusion criteria: 1. Other malignancies 2. Prior chemotherapy (excluding estramuscin) 3. Steroids 4. Severe visceral dysfunction 5. Other clinical trial 6. Prior enzalutamide or abiraterone

Design outcomes

Primary

Measure	Time frame
PSA resopnse	—

Secondary

Measure	Time frame
QOL Duration before chemotherapy Skeletal related event Survival	—

Countries

Japan

Contacts

Public ContactMitsuzuka Koji

Tohoku University School of Medicine Urology

mitsuzuka@uro.med.tohoku.ac.jp022-717-7278

Outcome results